Organon Pharma Indonesia Tbk. vs Bersama Zatta Jaya Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Bersama Zatta Jaya Tbk. trades at Rp67 (market cap 586.22B, 51.53M 24h volume). The key difference: Bersama Zatta Jaya Tbk. is far larger — about 5.6× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | ZATA | |
|---|---|---|
Market Cap | 104.4B | 586.22B |
Volume | — | 51.53M |
Lot | — | 515.28K |
Turnover | — | 3.45B |
Average Price | — | 67.05 |
Value | — | 3.45B |
Indicative Equilibrium Price | — | 67 |
Indicative Equilibrium Volume | — | 9.49K |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Bersama Zatta Jaya Tbk (the Company) was established based on notarial deed No. 39 datedApril 16, 2012 of Ermilla Ananta Cahyani,S.H., notary in Bandung. The company started its commercial activities since 2012.
Read more on ZATA →